
<!DOCTYPE article
  PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" article-type="correction" xml:lang="en"><processing-meta tagset-family="jats" base-tagset="archiving" mathml-version="3.0" table-model="xhtml"><custom-meta-group><custom-meta assigning-authority="highwire" xlink:type="simple"><meta-name>recast-jats-build</meta-name><meta-value>d8e1462159</meta-value></custom-meta></custom-meta-group></processing-meta><front><journal-meta><journal-id journal-id-type="hwp">jitc</journal-id><journal-id journal-id-type="nlm-ta">J Immunother Cancer</journal-id><journal-id journal-id-type="publisher-id">jitc</journal-id><journal-title-group><journal-title>Journal for ImmunoTherapy of Cancer</journal-title><abbrev-journal-title abbrev-type="publisher">J Immunother Cancer</abbrev-journal-title><abbrev-journal-title>J Immunother Cancer</abbrev-journal-title></journal-title-group><issn pub-type="epub">2051-1426</issn><publisher><publisher-name>BMJ Publishing Group Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">jitc-2020-000878corr1amendment</article-id><article-id pub-id-type="doi">10.1136/jitc-2020-000878corr1Amendment</article-id><article-id pub-id-type="apath" assigning-authority="highwire">/jitc/8/2/e000878corr1Amendment.atom</article-id><article-categories><subj-group subj-group-type="heading"><subject>Correction</subject></subj-group><subj-group subj-group-type="collection" assigning-authority="publisher"><subject>Open access</subject></subj-group><subj-group subj-group-type="collection" assigning-authority="highwire"><subject>Special collections</subject><subj-group><subject>Open access</subject></subj-group></subj-group></article-categories><title-group><article-title>Amendment to '<italic toggle="yes">Correction: Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19'</italic>
</article-title></title-group><pub-date date-type="pub" iso-8601-date="2020-08" pub-type="ppub" publication-format="print"><month>8</month><year>2020</year></pub-date><pub-date date-type="pub" iso-8601-date="2020-08-20" pub-type="epub-original" publication-format="electronic"><day>20</day><month>8</month><year>2020</year></pub-date><pub-date iso-8601-date="2020-06-29T04:33:09-07:00" pub-type="hwp-received"><day>29</day><month>6</month><year>2020</year></pub-date><pub-date iso-8601-date="2020-06-29T04:33:09-07:00" pub-type="hwp-created"><day>29</day><month>6</month><year>2020</year></pub-date><volume>8</volume><issue>2</issue><elocation-id>e000878corr1Amendment</elocation-id><permissions><copyright-statement>© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</copyright-statement><copyright-year>2020</copyright-year><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xlink:type="simple"><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2020-08-20">http://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xlink:type="simple">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="jitc-2020-000878corr1Amendment.pdf" xlink:type="simple"/><related-article ext-link-type="doi" related-article-type="corrected-article" xlink:href="10.1136/jitc-2020-000878" id="RA1" xlink:type="simple"/><related-article ext-link-type="doi" related-article-type="corrected-article" xlink:href="10.1136/jitc-2020-000878corr1" id="RA2" xlink:type="simple"/><custom-meta-group><custom-meta xlink:type="simple"><meta-name>special-feature</meta-name><meta-value>unlocked</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Correction: Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19<italic toggle="yes">. J Immunother Cancer</italic> 2020;<bold>8:</bold>e000878corr1. doi: 10.1136/jitc-2020-000878corr1</p><p>This correction notice incorrectly stated that Kim Margolin’s middle initial was ‘M’ instead of ‘A’ in the first paragraph.</p><p>The first paragraph should instead read, ‘The following authors were missing the middle initials in their names; Bernard A Fox, Walter J Urba, Julie R Brahmer, Daniel S Chen, Tanja D de Gruijl, F Stephen Hodi Jr, Howard L Kaufman, Michael T Lotze, Kim A Margolin, Francesco M Marincola. The author name Jon M Wigginton was also spelt incorrectly as Jon M Wiggington. The author list is shown below and has been updated in the article.’</p><p>Paolo Antonio Ascierto, Bernard A Fox, Walter J Urba, Ana Carrizosa Anderson, Michael B Atkins, Ernest C Borden, Julie R Brahmer, Lisa H Butterfield, Alessandra Cesano, Daniel S Chen, Tanja D de Gruijl, Robert O Dillman, Charles G Drake, Leisha A Emens, Thomas F Gajewski, James L Gulley, F Stephen Hodi Jr, Patrick Hwu, David Kaufman, Howard L Kaufman, Michael T Lotze, Douglas G McNeel, Kim A Margolin, Francesco M Marincola, Michael J Mastrangelo, Marcela V Maus, David R Parkinson, Pedro J Romero, Paul M Sondel, Stefani Spranger, Mario Sznol, George J Weiner, Jon M Wigginton and Jeffrey S Weber</p></body></article>